C. Graham

发表

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

P. Emery, M. van Keep, S. Beard, 2018, PharmacoEconomics.

Cost-Effectiveness In The Second-Line Treatment Of Non-Small Cell Lung Cancer (Nsclc) In The Us.

C. Graham, M. Jen, L. Hess, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost Analyses in the US and Japan: A Cross-Country Comparative Analysis Applied to the PRONOUNCE Trial in Non-Squamous Non-Small Cell Lung Cancer

C. Graham, L. Hess, K. Winfree, 2015, Advances in Therapy.

Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on‐demand with bypass treatment

C. Kessler, J. Spears, C. Graham, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Mean lifetime survival estimates following solid organ transplantation in the US and UK

M. Stevenson, C. Graham, V. Dharnidharka, 2022, Journal of medical economics.

Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective

C. Graham, A. Igarashi, A. Igarashi, 2018, Journal of medical economics.

Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.

A. Briggs, P. Parfrey, G. Chertow, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis

G. Auzinger, C. Charbonneau, C. Graham, 2015, BMC Infectious Diseases.

Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia

G. Auzinger, C. Charbonneau, C. Graham, 2013, Critical Care.

Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation.

M. Schnitzler, W. Irish, C. Graham, 2008, Journal of the American Society of Nephrology : JASN.

Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.

B. Barber, C. Graham, G. Hechmati, 2014, European journal of cancer.

P159 Attacks avoided and cost offsets associated with subcutaneous C1-inhibitor (human) long-term prophylaxis of hereditary angioedema

T. Machnig, G. Krishnarajah, D. Supina, 2017 .

Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

M. Fakih, B. Barber, C. Graham, 2015, Journal of medical economics.

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults

S. Sullivan, E. Simpson, L. Eckert, 2017, Dermatology and Therapy.

A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US

C. Graham, J. Strickler, G. Hechmati, 2018, Journal of medical economics.

Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.

J. Javitt, Sonali N. Shah, A. Adamis, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates

B. Ettinger, M. Amonkar, C. Graham, 2007, Current medical research and opinion.

Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective

R. Goeree, D. Gladman, C. Graham, 2018, Journal of medical economics.

Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study

Yang Zhao, S. Feldman, C. Graham, 2018, Journal of managed care & specialty pharmacy.

Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia.

H. Ascher-Svanum, J. Mauskopf, C. Graham, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.

M. Fakih, T. Price, B. Barber, 2016, Clinical therapeutics.

Cost-effectiveness analysis of panitumumab plus mFOLFOX 6 compared with bevacizumab plus mFOLFOX 6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

B. Barber, C. Graham, G. Hechmati, 2014 .

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

R. Warren, C. Graham, L. Miles, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Cost‐effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany

M. Augustin, C. Graham, C. O’Neill, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK

B. Kirkham, C. Graham, L. Miles, 2018, PharmacoEconomics.

Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.

G. de Pouvourville, B. Barber, C. Graham, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

PEY11 COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION: COMPARING EARLY AND LATE MACUGEN TREATMENT

Sonali N. Shah, A. Adamis, G. Zlateva, 2005 .

PEY9 COST-EFFECTIVENESS MODEL FORAGE-RELATED MACULAR DEGENERATION: COMPARING MACUGEN TO VISUDYNE

Sonali N. Shah, A. Adamis, G. Zlateva, 2005 .